Medical Condition News

RSS

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

9 Jul 2012

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

9 Jul 2012

BioView, ScreenCell enter collaboration agreement for imaging of CTC

BioView Ltd. and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit.

9 Jul 2012

Health Canada approves XIAFLEX for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada.

9 Jul 2012

Stroke Telemedicine: An interview with Séamus Watson

Stroke is the third largest cause of death in England. (1) It is a condition that requires rapid assessment and treatment to reduce deaths, disability and the risk of having another stroke. (2)

9 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Regnite to treat primary restless legs syndrome launched in Japan

Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

9 Jul 2012

Acusphere completes MAA dossier for Imagify to detect CAD

Acusphere, Inc. today announced that it had completed the Marketing Authorisation Application dossier for its lead product candidate, Imagify (Perflubutane Polymer Microspheres) for Injectable Suspension, and is now starting the process of filing the MAA dossier with the European Medicines Agency to support the regulatory review of Imagify in the European Union.

9 Jul 2012

Researchers use metal complexes to modify peptide hormones

Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds.

9 Jul 2012

Novel system to treat hair loss receives CE Mark approval

Restoration Robotics, Inc., a privately-held medical device company, today announced its revolutionary ARTAS System received CE Mark Certificate to market in the European Union. The ARTAS System is the first physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp.

9 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012

Novel treatment for cancer based on protein from HIV-1 virus

Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

OrSense launches Glasswing for anemia monitoring and hemorrhage detection

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, Glasswing, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation screening.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

FDA approves Capricor’s IND application for myocardial infarction study

Capricor, Inc., a privately held biotechnology company focused on regenerative medicine, today announced that the U.S. Food and Drug Administration has approved initiation of its Investigational New Drug (IND) application for the ALLSTAR study, which will use allogeneic cardiac-derived stem cells (CDCs) to treat patients following large myocardial infarctions (MI).

9 Jul 2012

Long Beach Memorial uses Toshiba's Aquilion ONE to expand stroke care capabilities

To expand its stroke care capabilities for fast diagnoses and more accurate treatment, Long Beach Memorial, a primary stroke care center for MemorialCare Health System, is using Toshiba's Aquilion ONE dynamic volume CT system for both acute stroke diagnoses and interventional planning.

9 Jul 2012

Recovery may be lifelong process for children with brain injury

In the last ten years, a new understanding of pediatric brain injury and recovery has emerged. Professionals now understand that recovery may be a lifelong process for the child's entire circle of family, friends, and healthcare providers. The latest efforts to advance medical and rehabilitative services to move children from medical care and rehabilitation to community reintegration are discussed by the leading experts in a recently published special issue of NeuroRehabilitation.

9 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012